{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ABT",
  "name": "Abbott Laboratories",
  "url": "https://orbyd.app/dossiers/ABT/",
  "json_url": "https://orbyd.app/dossiers/ABT.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Post-deal de-rating unwinding: the 2026-07-16 Q2 beat (sales $12.593B, adj EPS $1.31 vs $1.28) plus the first FY26 guidance raise of the year to $5.45–$5.60, then FDA approval of Freenome's SimpleScreen CRC blood test on 2026-07-27, which Abbott commercializes from fall 2026. Price has reclaimed the 20/50/100-day; the 200-day at $108.35 is still overhead.",
  "invalidation_trigger": "A weekly close below $95 surrenders the 2026-07-16 post-Q2 gap and the reclaimed 50-day average; secondarily, the FY26 comparable range of 6.5%–7.5% being trimmed at the Q3 report (~mid-October 2026) rather than reaffirmed removes the second-half acceleration the July move was priced on.",
  "catalyst_date": "2026-08-28",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Reported growth includes Exact Sciences (closed 2026-03-23) through Q1 2027; Q2's 13.0% reported versus 4.8% comparable is the size of that gap.",
    "NEC preterm-formula litigation (MDL 3026, N.D. Illinois, 810 cases pending as of July 2026) is unquantified and verdicts arrive on no fixed calendar.",
    "Abbott's \"comparable\" sales measure strips FX and certain acquisition effects; the reported line and the guided line are not on the same basis.",
    "Quarterly dividend $0.63/share, $2.52 annualized. Abbott carries a decades-long dividend-increase record, so any rate decision reads as a post-deal capital-allocation signal."
  ],
  "body_markdown": "## Current Thesis\n\nAbbott spent the first half of 2026 being de-rated for an acquisition. The Exact Sciences purchase closed 2026-03-23 at $105/share cash — roughly $21B in equity and about $23B enterprise value including ~$1.8B of assumed net debt — and carried approximately $0.20 of FY26 adjusted-EPS dilution. Stacked on a weak respiratory season and China volume-based procurement in Core Lab Diagnostics, that took the stock from a 52-week high of $137.49 to an intraday low of $81.97 on 2026-05-11 (close $82.56).\n\nThe 2026-07-16 Q2 print was the first hard evidence the de-rating had overshot. Sales of $12,593M (+13.0% reported, +4.8% comparable) against roughly $12.48B consensus, adjusted diluted EPS of $1.31 against $1.28, GAAP diluted EPS $0.53, and FY26 adjusted EPS guidance lifted to $5.45–$5.60 from $5.38–$5.58. Shares gained more than 10% in that session. Eleven days later, on 2026-07-27, the FDA approved Freenome's SimpleScreen CRC blood test, which Abbott exclusively commercializes in the US from fall 2026 in exchange for a $100M milestone payment to Freenome — putting stool-based (Cologuard) and blood-based colorectal screening under the same roof.\n\nThe narrative leg on offer is the unwind of a deal-driven multiple compression, with cardiac devices funding the ramp in the acquired diagnostics assets. Medical Devices grew 8.4% comparable to $5,853M in Q2, electrophysiology +13.4%, and Volt pulsed-field ablation was FDA-approved on 2025-12-22.\n\n## Bull Case\n\n- **Q2 2026 double beat (2026-07-16)** — sales $12,593M, +13.0% reported and +4.8% comparable, against roughly $12.48B consensus; adjusted diluted EPS $1.31 against $1.28.\n- **First guidance raise of 2026** — the FY26 adjusted-EPS range went $5.55–$5.80.38–$5.58 at the 2026-04-16 Q1 report → raised to $5.45–$5.60 on 2026-07-16. Q3 2026 adjusted EPS guided $1.38–$1.46.\n- **The cardiac line is carrying growth** — Medical Devices $5,853M, +8.4% comparable; electrophysiology +13.4%; structural heart +5.7%; CGM +9.5% comparable with FreeStyle Libre quarterly sales above $2B (Q2 2026 release and call).\n- **The acquired asset is compounding** — cancer diagnostics revenue +13% with Cologuard growing mid-teens; on the 2026-07-16 call management attributed expected H2 acceleration to health systems running care-gap programs tied to HEDIS and CMS Star ratings.\n- **2026-07-27 FDA approval, SimpleScreen CRC** — the PREEMPT CRC study enrolled more than 48,000 asymptomatic average-risk adults across 200+ sites; 81.1% sensitivity for colorectal cancer and 90.4% specificity for advanced colorectal neoplasia. US launch scheduled for fall 2026.\n- **Insiders bought the drawdown** — director John Stratton bought 2,000 shares at $86.82 on 2026-05-07 (Form 4 filings).\n- **Dated pipeline steps** — Amulet 360 left atrial appendage FDA submission completed May 2026; TECTONIC coronary intravascular lithotripsy pivotal enrollment completed April 2026.\n\n## Bear Case\n\n- **The full-year guide implies a step-up Q2 did not deliver.** FY26 comparable sales growth was reaffirmed at 6.5%–7.5% while Q2 comparable growth printed 4.8%. The second half has to carry that difference.\n- **Nutrition is shrinking** — $2,144M in Q2 2026, -3.6% comparable, the only division in outright decline.\n- **Diagnostics is barely growing** — $3,092M, +2.9% comparable, with China volume-based procurement still pressuring Core Lab and management holding a cautious China stance since the 2026-04-16 Q1 call.\n- **NEC litigation is open-ended** — 810 preterm-formula cases pending in MDL 3026 before Judge Rebecca Pallmeyer (N.D. Ill.) as of July 2026. A Chicago jury awarded $53M compensatory on 2026-04-09 and $17M punitive on 2026-04-10; a Missouri appeals court declined on 2026-06-24 to refer the $495M 2024 verdict to that state's supreme court.\n- **The upside case is already the consensus case** — mean price target $118.42 across 27 analysts against a $105.70 close on 2026-07-31, and UBS cut its target from $135 to $125 on 2026-07-28 while keeping a Buy rating.\n- **Valuation is not distressed** — trailing P/E 34.20, forward P/E 18.23, market cap $182.90B at the 2026-07-31 close.\n\n## Setup & Price Structure\n\nClose $105.70 on 2026-07-31, inside a 52-week range of $81.97–$137.49. The recovery path is dated: $88.41 on 2026-06-18, $100.68 on 2026-07-17 after the Q2 gap, $105.70 on 2026-07-31.\n\nMoving averages at 2026-07-31 (Barchart): 20-day $99.08, 50-day $93.30, 100-day $95.34, 200-day $108.35. Price sits above the three shorter averages and below the 200-day, which is the one overhead line that matters at these levels. 14-day RSI 66.77.\n\n**Life-cycle: ACCELERATING.** The dates carry the label — a greater-than-10% single-session move on 2026-07-16, eight sell-side target actions on 2026-07-17 (six raises: BTIG to $134, JPM to $120, Evercore to $120, Piper Sandler to $118, Citigroup to $112, Wells Fargo to $112; RBC maintained $130 and TD Cowen maintained $115), and a fresh FDA approval on 2026-07-27. Attention is returning to a name the market discarded between March and May.\n\n**Crowding and positioning observables:** RSI 66.77 with price well above a 20-day at $99.08; the 200-day at $108.35 not yet reclaimed; target dispersion of $112–$134 from the 2026-07-17 cluster around a $118.42 mean; UBS trimming $135 to $125 into strength on 2026-07-28; no scheduled earnings date until the Q3 report expected mid-October; 2026 insider activity skewed to open-market buying at $86.82–$91.50 in April and May against an EVP open-market sale of 613 shares at $115.58 on 2026-03-02.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-17** — quarterly dividend of $0.63/share payable (record date 2026-07-15), annualizing $2.52 against a 2.38% yield at the 2026-07-31 close.\n- **2026-08-28 to 2026-08-31** — ESC Congress 2026, Messe München. Late-breaking cardiology data frames the pulsed-field ablation contest against Boston Scientific, Medtronic and J&J — the line that produced Q2's 13.4% electrophysiology growth.\n- **~2026-10-01 (est.)** — SimpleScreen CRC US commercial launch, described as \"fall 2026\" in the 2026-07-27 approval release. First pricing and reimbursement datapoints.\n- **~2026-10-15 (est.)** — Q3 2026 results against the $1.38–$1.46 adjusted-EPS guide and the reaffirmed 6.5%–7.5% FY comparable range.\n\nNo Abbott-specific regulatory decision or guidance event is confirmed inside the 30-day window. The Amulet 360 FDA submission completed in May 2026 has no published decision date.\n\n## What Would Change Our Mind\n\nThe structure that has to hold is the 2026-07-16 repricing gap. Price left a shelf in the low-to-high $90s when it moved on the Q2 beat — it traded $88.41 as recently as 2026-06-18 and closed $100.68 on 2026-07-17. A return into that shelf would mean the market read the raise as a one-quarter consolidation artifact rather than a change in the underlying rate. Concretely, a weekly close below $95 surrenders that gap and the reclaimed 50-day average and puts price back inside the range it occupied from March through mid-July.\n\nTwo non-price conditions carry comparable weight. If the FY26 comparable range of 6.5%–7.5% is trimmed at the October report instead of reaffirmed, the second-half acceleration that justified the July move is gone and Q2's 4.8% becomes the run rate. If the 200-day at $108.35 is tested and rejected without a close through it while the shorter averages flatten, the life-cycle label moves from ACCELERATING to MATURING regardless of what the prints say.\n\nA fresh adverse NEC verdict of material size, or a litigation reserve disclosed against MDL 3026, would reopen the discount the stock carried through May.\n\n## Correlation Notes\n\n- **US procedure volumes are the shared factor across large-cap medtech.** Intuitive Surgical fell 11% on 2026-07-17 after warning that insurance changes could slow US procedure growth; Abbott closed $100.68 that same session on its own beat. Medical Devices at +8.4% comparable rests on the same procedure base, so that commentary spreading through Q3 medtech reports is a read-through risk.\n- **Pulsed-field ablation is a share fight, not a rising tide.** Boston Scientific, Medtronic and J&J were in the US PFA market before Abbott's 2025-12-22 Volt approval, so competitor electrophysiology disclosures bear directly on whether ABT's 13.4% EP growth persists.\n- **Cancer diagnostics now links ABT to the screening complex** through reimbursement and guideline decisions rather than through procedure counts — coverage determinations for blood-based CRC screening move Cologuard and SimpleScreen economics together.\n- **Defensive behaviour on 2026-07-17** — the Nasdaq fell 1.5% and the CNN sentiment gauge moved into its \"Fear\" zone in the session ABT closed at $100.68 on results.",
  "first_seen": "2026-07-31",
  "last_analyzed": "2026-08-01T07:08:23+00:00",
  "last_synthesized": "2026-08-01",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}